Form 4: Sage Therapeutics COO Acquires Stock Options and Restricted Stock Units

Sage Therapeutics' Chief Operating Officer, Christopher Benecchi, was granted stock options and restricted stock units as part of the company's 2024 Equity Incentive Plan.

Summary

• Christopher Benecchi, Chief Operating Officer of Sage Therapeutics, received 6,250 restricted stock units (RSUs) and options to purchase 12,500 shares of common stock on November 1, 2024.
• The RSUs vest in equal annual installments over four years, starting November 1, 2025.
• The stock options also vest over four years, with 25% vesting on November 1, 2025, and the remainder vesting monthly thereafter.
• These grants are part of the Sage Therapeutics, Inc. 2024 Equity Incentive Plan and are subject to continued service by Mr. Benecchi.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. There are no indications of negative sentiment.

Positives

• The equity grants align the COO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the COO.
• The grants are part of a formal equity incentive plan.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Sage Therapeutics' stock price.
• The vesting of the grants is contingent on the COO's continued employment with the company.

Future Outlook

The vesting of the stock options and RSUs is contingent on the continued service of the COO, suggesting a long-term commitment.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in the biotech industry.
• Vesting schedules of four years are typical for these types of grants, aligning with long-term company performance goals.
• The specific terms of the grant, such as the exercise price and vesting schedule, are consistent with industry norms for companies of Sage Therapeutics' size and stage.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity incentive plan, insider trading, executive compensation, Sage Therapeutics, SAGE